Long-Term Unknowns in New Interventions
Why the long-term effects of a new treatment are often not known at approval, how the FDA handles this for gene therapies, and one CAR T example of a risk found after approval.
Content last updated . This page has not been medically reviewed.
Why trials cannot answer everything
The FDA describes Phase 3 trials as involving 300 to 3,000 participants. It says less common side effects might have gone undetected in earlier studies, and that because Phase 3 studies are larger and longer, they are more likely to show long-term or rare side effects. [1] For drugs, the FDA also says it is impossible to have complete information about a drug's safety at the time of approval, and that the true picture of safety evolves over the months and years a product is on the market. [2]Early-stage studies are smaller and shorter still. See clinical-trial phases explained and feasibility, safety and efficacy studies.
Gene therapies: why follow-up is built in
In its January 2020 guidance on long-term follow-up (LTFU) after human gene therapy products, the FDA notes that these products are often designed to achieve effect through permanent or long-acting changes in the body. [3] It says that as a result, people exposed in trials may face increased risk of undesirable and unpredictable outcomes that appear as delayed adverse events. [3]The guidance recommends different follow-up lengths by product type. In the United States, for integrating vectors such as gammaretroviral and lentiviral vectors and transposon elements, it recommends fifteen years. [4] It cites the risk of leukemias and premalignant conditions from vector integration as a reason for added data collection. [4] The guidance also says that the recommended follow-up period often will not have elapsed for all trial subjects before a product is licensed, so post-marketing monitoring plans matter. [4]
The FDA states that not all gene therapy products will require LTFU observations, and that a sponsor's risk assessment decides. [3] These recommendations are addressed to sponsors developing gene therapy products. They do not describe what any particular clinic does.
What stays unknown when nobody is following patients
Where no organized follow-up exists, delayed harms may simply not be counted. That is a limitation to keep in mind, not a finding. Also keep apart a lab or blood-test change from a lasting health outcome. See surrogate vs patient-important outcomes.Questions worth asking
- How long have people been followed after this treatment, and for what?
- Is this product approved, or investigational? For which condition? See approved product vs approved indication.
- Is there a registry or follow-up plan, and who reports problems? See adverse-event reporting for emerging products.
Related guides
Gene addition and gene therapy explained and viral vectors in gene therapy.Frequently asked questions
Does "no reported side effects" mean a new treatment is safe?
Not by itself. The FDA says trials cannot provide complete safety information at approval and that safety evolves over years on the market. [2] A short or small study may miss rare or late effects. [1]
How long are gene therapy patients followed?
FDA recommendations depend on product type. For U.S. trials of integrating vectors, the FDA guidance recommends fifteen years of long-term follow-up. [4] Other product types have different recommendations.
Why are CAR T products followed for life?
After reports of T cell malignancies with these approved BCMA- and CD19-directed products, the FDA said patients and trial participants should be monitored life-long for secondary malignancies. [5]
Does an approved drug have all its long-term risks known?
No. For drugs, the FDA says complete safety information is impossible at approval and that the picture evolves over the years a product is on the market. [2]
Where do I report a problem?
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
A real example: a risk found after approval
This example shows how a safety signal can emerge from reports gathered after approval. The FDA said reports came from clinical trials and/or postmarketing adverse event data, and had also listed the issue as a potential signal in its FAERS quarterly report. [5] It does not show that every cell or gene product carries this risk, and it says nothing about whether any product's benefits outweigh its risks.
References
- U.S. Food and Drug Administration. Step 3: Clinical Research. Read 2026-10-22.
- U.S. Food and Drug Administration. Step 5: FDA Post-Market Drug Safety Monitoring. Read 2026-10-22.
- U.S. Food and Drug Administration. Long Term Follow-up After Administration of Human Gene Therapy Products (guidance landing page, January 2020). Read 2026-10-22.
- U.S. Food and Drug Administration. Long Term Follow-up After Administration of Human Gene Therapy Products: Guidance for Industry (full text, January 2020). Read 2026-10-22.
- U.S. Food and Drug Administration. FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. April 18, 2024. Read 2026-10-22.